Trial reportOphthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)2026
Effects of HP-Guar Nano-emulsion Artificial Tears on Symptoms and Severity of Meibomian Gland Dysfunction in Evaporative Dry Eye During a 90-Day Longitudinal Study.
Trial report in Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundTo evaluate whether hydroxypropyl-guar (HP-Guar) nano-emulsion artificial tears improve symptoms, quality of life, severity of meibomian gland dysfunction (MGD) and evaporative dry eye (EDE)-related parameters in mild-to-moderate EDE participants over 90 days.
methodsFifty-one mild-to-moderate EDE participants were recruited for a single-masked, longitudinal clinical trial without a control group or placebo. Inclusion criteria comprised: Ocular Surface Disease Index (OSDI) between 13-32 points; at least one positive diagnostic sign (Non-Invasive Tear Break-Up Time [NIBUT] <10 s and/or corneal staining >1) and two classification signs (Tear Meniscus Height [TMH] ≥0.20 and ≤0.50 mm and MGD score ≥5 points). Participants applied 1-2 drops of HP-Guar nano-emulsion artificial tears per eye, four times daily for 90 days, with follow-up assessments at baseline, 30, 60 and 90 days. Three groups of tests were conducted each session: DED symptomatology and quality of life (OSDI, EuroQol 5-Dimension 5-Level [EQ-5D-5L]), MGD severity (MGD score, meibomian gland loss area [MGLA]) and EDE-related parameters (meibomian gland expression [MGE], Meibometry, lipid layer pattern (LLP), NIBUT, ocular redness and corneal staining).
resultsSignificant differences in OSDI score, EQ-5D-5L in the 'Healthy today' scale, MGD score, lower eyelid MGLA and LLP were observed across sessions (all p ≤ 0.03). However, no significant differences were found in EQ-5D-5L score, upper eyelid MGLA, MGE, Meibometry, NIBUT-first, NIBUT-average, limbal or bulbar redness in any area or corneal staining (all p ≥ 0.09).
conclusionsThis 90‑day single‑masked study without a control group found that HP‑Guar nano‑emulsion eye drops were associated with improvements in symptoms, perceived health and MGD‑related signs. These findings are exploratory and require confirmation in controlled trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.